chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Seven minutes after injection, blood pressure became extremely elevated. Dizziness, facial flushing and pressure behind the eyes. General feeling of being drunk and confused.  I took my blood pressure and it was 182 over 102.  I took half of 5 MG bystolic and blood pressure decreased.  Overall blood pressure and disoriented feeling persisted for 3 plus hours.  2 weeks later, blood pressure is still not under control. Randomly, blood pressure will shoot up out of control since date of vaccination. Working on appointment with cardiologist.
Over the weekend of the vaccine, I felt nausea similar to morning sickness but I'm 30 weeks so I'm a little far along for that it went from sat-tues. I've had acid reflux with the pregnancy but didn't think much of it. On Tuesday, I started having more fatigue and a little bit of throat pain. By Wed morning, I basically had laryngitis and can't speak very well and was coughing. By Thursday morning, I was coughing up green phlegm and had a bit of heaviness in my chest. I called my doctors and ended up being seen at urgent care and they diagnosed me with a sinus infection. I did a antigen home covid test yesterday and it was negative. I haven't had a lot of interaction with people. My husband has a sinus infection so the DR was comfortable saying that's what I have. They gave me a zpack. This is my 2nd pregnancy. August 2nd is the assumed delivery date.
Slept the entire day; fatigued; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSOMNIA (Slept the entire day) and FATIGUE (fatigued) in an 85-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L02A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, the patient experienced HYPERSOMNIA (Slept the entire day) and FATIGUE (fatigued). At the time of the report, HYPERSOMNIA (Slept the entire day) and FATIGUE (fatigued) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The concomitant medications  were not reported.  The treatment medications were not  provided
cough; hoarseness; This is a spontaneous report received from contactable reporter(s) (Other HCP and Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), in Mar2023 as dose number unknown (booster), single (Batch/Lot number: unknown) at the age of 70 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete but unknown manufacturer), for COVID-19 Immunization. The following information was reported: COUGH (non-serious), outcome "recovering"; DYSPHONIA (non-serious), outcome "recovering", described as "hoarseness".  Additional information: The patient reported receiving a covid booster shot (Pfizer) two weeks ago. Patient developed a new onset of cough and hoarseness (present) improved; MD is aware. The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Menstrual period was four days late with negative pregnancy test; Extreme cramping; heavy bleeding; This is a spontaneous report from a non-contactable nurse. A 30-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an intramuscular route of administration, administered in right arm on 16Apr2021 07:00 (Batch/Lot Number: Ew0150) (at the age of 30-years-old) as 1st dose, single for COVID-19 immunisation. Medical history included penicillin (PCN) allergy. The patient's concomitant medications were none. The patient previously took nitrofurantoin (MACROBID) and experienced nitrofurantoin allergy. The patient didn't receive other vaccine in four weeks and didn't receive other medications in two weeks. The patient did not have COVID prior vaccination and didn't test for COVID post vaccination. The patient stated that her menstrual period was four days late with negative pregnancy test and experienced extreme cramping and heavy bleeding on 21Apr2021 08:00. The patient underwent lab tests and procedures which included pregnancy test: negative on an unspecified date. The patient was treated with ibuprofen (ADVIL). The outcome of events, menstrual period was four days late with negative pregnancy test, extreme cramping and heavy bleeding, was recovered on an unspecified date.   No follow-up attempts are possible. No further information is expected.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. No concurrent condition, medical history or allergy/drug reactions were reported. On 26-OCT-2015 08:59, the patient was vaccinated with improperly stored RECOMBIVAX HB with lot number: L016427, expiry date: 13-APR-2017 (dose and strength unspecified). No concomitant medications were reported. No adverse effects were reported. The high temperature and low temperature were 6.0 and 2.8 respectively. There were no product quality complaints (PQC) involved. No additional information was provided. This is one of the several reports from the same reporter. Additional information has been requested.
This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 58 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 28Nov2021 12:00 (Lot number: 320308D) at the age of 58 years as dose 3 (booster), single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: ZOLPIDEM. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: ER8729, Location of injection: Arm Left, Vaccine Administration Time: 02:30 PM), administration date: 08Apr2021, when the patient was 58 years old, for Covid-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: ER2613, Location of injection: Arm Left, Vaccine Administration Time: 10:30 AM), administration date: 19Mar2021, when the patient was 58 years old, for Covid-19 immunization. The following information was reported: IMMUNISATION (non-serious) with onset 28Nov2021 12:00, outcome "unknown", described as "Dose Number: 3"; FATIGUE (non-serious) with onset 29Nov2021 02:00, outcome "not recovered", described as "Extreme fatigue"; COUGH (non-serious) with onset 29Nov2021 02:00, outcome "not recovered", described as "chronic cough"; HEADACHE (non-serious) with onset 29Nov2021 02:00, outcome "not recovered", described as "headache"; RALES (non-serious) with onset 29Nov2021 02:00, outcome "not recovered", described as "chest/lung rattles"; DYSPNOEA (non-serious) with onset 29Nov2021 02:00, outcome "not recovered", described as "shortness of breath at times"; SINUS CONGESTION (non-serious) with onset 29Nov2021 02:00, outcome "not recovered", described as "sinus congestion"; ASTHENIA (non-serious) with onset 29Nov2021 02:00, outcome "not recovered", described as "general weakness"; SNEEZING (non-serious) with onset 29Nov2021 02:00, outcome "not recovered", described as "occasional sneezing"; LACRIMATION INCREASED (non-serious) with onset 29Nov2021 02:00, outcome "not recovered", described as "eyes tearing up"; CHEST DISCOMFORT (non-serious) with onset 29Nov2021 02:00, outcome "not recovered", described as "chest tightness". The events "extreme fatigue", "chronic cough", "headache", "chest/lung rattles", "shortness of breath at times", "sinus congestion", "general weakness", "occasional sneezing", "eyes tearing up" and "chest tightness" were evaluated at the physician office visit and emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of fatigue, cough, headache, rales, dyspnoea, sinus congestion, asthenia, sneezing, lacrimation increased, chest discomfort. Additional information: Patient did not receive any other vaccines within 4 weeks PRIOR to the COVID-19 vaccine. Patient had no allergy. Prior to vaccination, was the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. The patient received treatment with Steroids, antibiotics, nebulizer, inhaler.
EKG rythm was off; hurtful feeling in her jaw; hurtful feeling in the ear; This spontaneous case was reported by a consumer and describes the occurrence of ELECTROCARDIOGRAM ABNORMAL (EKG rythm was off), PAIN IN JAW (hurtful feeling in her jaw) and EAR PAIN (hurtful feeling in the ear) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ELECTROCARDIOGRAM ABNORMAL (EKG rythm was off), PAIN IN JAW (hurtful feeling in her jaw) and EAR PAIN (hurtful feeling in the ear). At the time of the report, ELECTROCARDIOGRAM ABNORMAL (EKG rythm was off), PAIN IN JAW (hurtful feeling in her jaw) and EAR PAIN (hurtful feeling in the ear) outcome was unknown.            Concomitant product was not provided. Treatment medication was not reported.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Ache at site of injection. Later that evening I had body aches over my entire body and had chills so bad my teeth chattered.  I took Tylenol, which didn?t help.  Had minor body aches the whole next day and took Alieve, which did help. Feel fine today (2 days later), with exception of minor soreness at injection site.
pt recv vax 1NOV96 & pt devel vomiting & diarrhea w/o fever 48hr p/inj;pharmacist related there was other pt that exp v, d who did not recv vax;this is one of 25 cases reported by a pharmacist;
Myalgia Narrative: Per nursing report: "took 2nd dose Moderna last Wednesday on 1-20- 21. States Wednesday night c/o sore right arm. Thursday morning could not pick arm up pass his shoulder. States was out the 21st and the 22nd. States arm feels better today."
THAT EVENING SHE GOT ITCHY AND SCRATCHY; THAT EVENING SHE GOT ITCHY AND SCRATCHY; HER ARM WAS RED AND INFLAMED; HER ARM WAS RED AND INFLAMED; This spontaneous case was reported by a consumer and describes the occurrence of SCRATCH (THAT EVENING SHE GOT ITCHY AND SCRATCHY), PRURITUS (THAT EVENING SHE GOT ITCHY AND SCRATCHY), VACCINATION SITE ERYTHEMA (HER ARM WAS RED AND INFLAMED) and VACCINATION SITE INFLAMMATION (HER ARM WAS RED AND INFLAMED) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Uveitis.    Previously administered products included for Product used for unknown indication: COVID-19 Vaccine (Dose 2, ROA : Intramuscular.), COVID-19 Vaccine (Dose 1 and ROA : Intramuscular.). Past adverse reactions to the above products included No adverse event with COVID-19 Vaccine and COVID-19 Vaccine.   In 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram. In 2021, the patient experienced SCRATCH (THAT EVENING SHE GOT ITCHY AND SCRATCHY), PRURITUS (THAT EVENING SHE GOT ITCHY AND SCRATCHY), VACCINATION SITE ERYTHEMA (HER ARM WAS RED AND INFLAMED) and VACCINATION SITE INFLAMMATION (HER ARM WAS RED AND INFLAMED). At the time of the report, SCRATCH (THAT EVENING SHE GOT ITCHY AND SCRATCHY) outcome was unknown and PRURITUS (THAT EVENING SHE GOT ITCHY AND SCRATCHY), VACCINATION SITE ERYTHEMA (HER ARM WAS RED AND INFLAMED) and VACCINATION SITE INFLAMMATION (HER ARM WAS RED AND INFLAMED) was resolving.            It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No concomitant medication were reported.  The reporters causality for the events of PATIENT RECEIVED BOOSTER VACCINE/THAT EVENING SHE GOT ITCHY AND SCRATCHY, PATIENT RECEIVED BOOSTER VACCINE/HER ARM WAS RED AND INFLAMED onset in 2021 and PATIENT RECEIVED BOOSTER VACCINE/HER ARM WAS RED AND INFLAMED onset in 2021 was not provided.  No treatment medication were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
This case was reported by a consumer via call center representative and described the occurrence of tiredness in a 59-year-old female patient who received SHINGRIX for prophylaxis. Previously administered products included SHINGRIX with an associated reaction of pyrexia (experienced after receiving 1st dose, refer case US2018GSK226605). On 12th December 2018, the patient received the 2nd dose of SHINGRIX. In December 2018, less than a week after receiving SHINGRIX, the patient experienced tiredness, cold and shivers. Rechallenge with SHINGRIX was positive. On an unknown date, the outcome of the tiredness, cold and shivers were unknown. It was unknown if the reporter considered the tiredness, cold and shivers to be related to SHINGRIX. Additional details were provided as follows: A day before reporting the patient received 2nd dose of SHINGRIX. The patient felt more of the tiredness, a little cold might be less severe than the 1st dose and little bit shivery more than last time. The patient did not felt fever after 2nd dose. The patient did not feel as bad overall. The patient asked was the ingredients in dose 1 and dose 2 were the same.
This spontaneous report was received from a physician and refers to a 2-year-old patient of an unknown gender. No information regarding the patient's pertinent medical history, concomitant medications, drug reactions or allergies was provided. On an unknown date, the patient was vaccinated with the first pediatric dose of VAQTA 25/ 0.5 (units were not provided), injection for prophylaxis (exact dose, route of administration, lot # and expiration date were not provided) at 1 year, 11 months of age. On an unknown date, the patient was vaccinated with the first pediatric dose of VAQTA 25/ 0.5 (units were not provided), injection for prophylaxis (exact dose, route of administration, lot # and expiration date were not provided) at 2 years, 1 month of age. The vaccinations were scheduled earlier than schedule. No adverse effects were reported. The outcome of event was not provided. The causality assessment was not reported.
Discrete scattered pinpoint papular rash to bilateral posterior shoulders, neck, bilateral forearms. Rash started on her arms and spread to her back and butt. It does itch.
EYESIGHT IMPROVED TO A POINT THAT PATIENT DID NOT NEED TO WEAR GLASSES; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. The patient's concurrent conditions included: patient was wearing glasses 15 years ago since the shot. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the patient experienced eyesight improved to a point that patient did not need to wear glasses. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of eyesight improved to a point that patient did not need to wear glasses was not reported. This report was non-serious.
This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash that covers torso of body/Rash that covers scalped), RASH PRURITIC (rash that itches) and HYPOACUSIS (Difficulty in hearing.) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination. No medical history is provided and concomitant drugs are provided. Concomitant products included BISOPROLOL FUMARATE, HYDROCHLOROTHIAZIDE (BISOPROLOL HCT), CALCIUM and VITAMINS NOS for an unknown indication. On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, the patient experienced RASH (Rash that covers torso of body/Rash that covers scalped), RASH PRURITIC (rash that itchies) and HYPOACUSIS (Difficulty in hearing.). At the time of the report, RASH (Rash that covers torso of body/Rash that covers scalped), RASH PRURITIC (rash that itchies) and HYPOACUSIS (Difficulty in hearing.) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. The patient took 2 Benadryl at 3 o´clock in the morning.
5/20/0 Two patients with a very close first name and same last name. Consulted he recommended to wait 15 months.
Background Patient received her  1st dose of Moderna: 2/11/21 2nd dose of Moderna: 3/11/21  Number of days post vaccine (today's date minus vaccine date): 5days   Initial reaction was noted on 2/11/21   Symptom Screening  Local Reaction  S/p 1st dose: 2/11/21: Pt noticed redness, "?looks like hives." on the left arm (on the injection site) and disappeared on its own 2 days later. Denies any SOB, breathing issues, lips or eyes swelling or any other concerning s/sx. "I felt fine."  Systematic Reaction:  S/P 2nd dose: Sxs Onset 3/11/21: Low grade fever: 99.8, headache, fatigue," jittering feeling." Pt stated. "All the symptoms went away on its own on 3/12/21 around 2 pm except the "jittery feeling."   Today on day 5  S/P2nd dose: Pt still continues to feel "jittery and hyper at times." Denies any anaphylactic reaction, dizziness, headache, fever, chills, breathing issues or any chest pain/discomfort.  Denies any other unusual S/SXs. Pt was able to speak clearly in full sentences. No distress noted. Pt is at work right now.   ALLERGIC Reaction  Did potential immediate allergic reaction (less than 4 hours after receiving vaccine) or anaphylaxis to first dose of the COVID vaccine occur? "Not exactly sure. Pt unable to express if it was an actual hives or just redness at the injection site."  Within 24 hours of vaccine administration,  did patient experience symptoms of a severe allergic reaction? "Not exactly sure. Pt unable to express if it was an actual hives or just redness at the injection site."    Assessment/Action Patient experienced a Moderate reaction to the vaccine. Symptoms  relieved with over the counter medications. No medication needed. Sxs resolved on its own expect the "Jittery and hyper feelings." Patient answered YES to mild-mod  Allergic Reaction  questions.  Patient was referred to allergy clinic for further evalution.  VAERS Complete: Yes. Patient experiencing any COVID-19 Symptoms AND >3 days post vaccine? NO  Response/Recommendation   Teaching -Provided education to patients per DPH guidelines as appropriate to the patient's clinical presentation.  -Educated the reasons to call the MGB Nurse hotline, PCP office and the reasons go to the nearest ED if symptoms change or worsen.   -Informed to make sure to call in advance if seeking medical care so sites can be prepared to receive the case.   -Good verbal return and agreed with the plan.
When we got home son was sleeping for very long time. It was impossible to wake him up. He was absolutely white and very cold. His fever was going from 104 to 95 in minutes. He was shaking. Next day he was sick with severe flu. We took him back to doctor office for a couple of times following week. His temperature was jumping up and down for a couple of days.
rash and itching: starting on back, then upper arm near shot location, then lower arms. Rash faded. Lower arms still itching and red.
After initial point soreness in my arm from the shot, my entire arm muscles became sore and weak. It is slowly getting better, but my muscles are still somewhat sore. This was after getting the second shot in the same arm as the first shot. At first , there was point soreness and swelling in different places around my arm (not at the site of the shot). Then it became an overall arm muscle soreness.
Cellulitis. Amoxicillin/Clavulanate 550/125 mg BID.
After 4 hours of getting the vaccine I was very tired , I started having body aches, chills and the left side of my face became numb. The numbness is  still  present until today. I was hoping it will go away but it didn?t.  What should I do? And is it ok to get the second shot? Thank you
Information has been received from a physician concerning a female patient who was vaccinated with a first 0.5 ml Gardasil (yeast). Subsequently the patient experienced a tingle and heaviness. Unspecified medical attention was sought. After twenty minutes the tingle and heaviness went away. No product quality complaint was involved. Additional information has been requested.
Two days following the vaccination, the patient experienced pain in the thoracic area that started under the breast and extended around the body to the middle of the back.  She also experienced difficulty breathing and was taken to the hospital.  She was diagnosed with fluid on her lungs and she had a procedure done to remove the fluid.  She was kept overnight for observation.
2/10/21 patient had been given COVID vaccine.  Later in the evening he had cough and headache and felt run down.  He then started with some shortness of breath and wheezing the next day.  He then used his inhaler to get through the symptoms quicker and it did help. Patient notes that within 22 hours of having the shot his symptoms then resolved.  He is not having any further issues or symptoms from the COVID vaccine at this time.
Rash with pimples on right side of body ie leg, stomach, shoulder, head, eye. Symptoms began four hours after vaccine and continued for about 10 days- symptoms were mild- Rash at injection site.
Extensive periorbital and midface Facial swelling associated with the site of prior dermal fillers (Restylane) placed about 6 months prior
Patient complained of red scaly and dry area on legs below knee and above ankle. He has slight discomfort due to rash. He is unsure if this is related to the ZOSTAVAX or present before. His md stated that the leg condition is eczema. He has a dry scaly scalp that is completely unrelated to the vaccine according to the patient. Patient is unsure of time course and unsure if this was present before the ZOSTAVAX but wanted to report.
Pt recvd rubella vax 3 days p/delivery; & over the period of a wk pt exp fevers & was treated w/unspecified ATB & Cephalexin; pt condition improved & was d/c 2DEC90; On 6DEC90 devel non pruritic, coalescing, blanching rash; Seen by MD;
Initial and follow-up information has been received from 62 year old female pharmacist prone to fever blister who on 05-DEC-2008 at 10:00 was vaccinated subcutaneously with a second dose of ZOSTAVAX (Oka/Merk) (lot # not available). Concomitant therapy included COUMADIN, ZOLOFT and LIPITOR. The patient presented with a large fever blister in her lips on 09-DEC-2008 approximately 4 days after receiving the vaccine. Patient gets fever blisters once or twice a year after exposure to sun or from upper respiratory infections. Neither event happened in December. In only unusual event was being immunized. The patient recovered on 12-DEC-2008. Additional information is not expected.